Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Anthony Smith

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
Experimental and Molecular Pathology|September 26, 2015
Multiple proliferation-survival signalling pathways are simultaneously active in BRAF V600E mutated thyroid carcinomasMd Atiqur Rahman, Ali Salajegheh, Robert Anthony Smith, et al.
International Journal of Colorectal Disease|August 6, 2010
Signet-ring cell carcinoma of colorectum--current perspectives and molecular biologyVinod Gopalan, Robert Anthony Smith, Yik-Hong Ho, et al.
Human Pathology|June 13, 2008
Quantitative analysis of survivin in colorectal adenocarcinoma: increased expression and correlation with telomerase activityAlfred King-Yin Lam, Said Saleh, Robert Anthony Smith, et al.
Experimental Cell Research|September 20, 2015
MicroRNA-126 suppresses proliferation of undifferentiated (BRAF(V600E) and BRAF(WT)) thyroid carcinoma through targeting PIK3R2 gene and repressing PI3K-AKT proliferation-survival signalling pathwayMd Atiqur Rahman, Ali Salajegheh, Robert Anthony Smith, et al.
Endocrine|May 16, 2016
Inhibition of BRAF kinase suppresses cellular proliferation, but not enough for complete growth arrest in BRAF V600E mutated papillary and undifferentiated thyroid carcinomasMd Atiqur Rahman, Ali Salajegheh, Robert Anthony Smith, et al.
Current Cancer Drug Targets|January 23, 2014
BRAF inhibitor therapy for melanoma, thyroid and colorectal cancers: development of resistance and future prospectsMd Atiqur Rahman, Ali Salajegheh, Robert Anthony Smith, et al.
Biochimie|February 22, 2017
Genetic alterations in Krebs cycle and its impact on cancer pathogenesisKarishma Sajnani, Farhadul Islam, Robert Anthony Smith, et al.
Annals of Diagnostic Pathology|December 17, 2013
Expression profile of endothelin 1 and its receptor endothelin receptor A in papillary thyroid carcinoma and their correlations with clinicopathologic characteristicsSoussan Irani, Ali Salajegheh, Vinod Gopalan, et al.
Human Pathology|December 21, 2010
Correlation between BRAF mutation and the clinicopathological parameters in papillary thyroid carcinoma with particular reference to follicular variantRobert Anthony Smith, Ali Salajegheh, Stephen Weinstein, et al.
Biology of the Cell|May 3, 2012
Epithelial-mesenchymal transition and mesenchymal-epithelial transition are essential for the acquisition of stem cell properties in hTERT-immortalised oral epithelial cellsBin Qiao, Vinod Gopalan, Zhifeng Chen, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Experimental and Molecular Pathology|September 26, 2015
Multiple proliferation-survival signalling pathways are simultaneously active in BRAF V600E mutated thyroid carcinomasMd Atiqur Rahman, Ali Salajegheh, Robert Anthony Smith, et al.
International Journal of Colorectal Disease|August 6, 2010
Signet-ring cell carcinoma of colorectum--current perspectives and molecular biologyVinod Gopalan, Robert Anthony Smith, Yik-Hong Ho, et al.
Human Pathology|June 13, 2008
Quantitative analysis of survivin in colorectal adenocarcinoma: increased expression and correlation with telomerase activityAlfred King-Yin Lam, Said Saleh, Robert Anthony Smith, et al.
Experimental Cell Research|September 20, 2015
MicroRNA-126 suppresses proliferation of undifferentiated (BRAF(V600E) and BRAF(WT)) thyroid carcinoma through targeting PIK3R2 gene and repressing PI3K-AKT proliferation-survival signalling pathwayMd Atiqur Rahman, Ali Salajegheh, Robert Anthony Smith, et al.
Endocrine|May 16, 2016
Inhibition of BRAF kinase suppresses cellular proliferation, but not enough for complete growth arrest in BRAF V600E mutated papillary and undifferentiated thyroid carcinomasMd Atiqur Rahman, Ali Salajegheh, Robert Anthony Smith, et al.
Current Cancer Drug Targets|January 23, 2014
BRAF inhibitor therapy for melanoma, thyroid and colorectal cancers: development of resistance and future prospectsMd Atiqur Rahman, Ali Salajegheh, Robert Anthony Smith, et al.
Biochimie|February 22, 2017
Genetic alterations in Krebs cycle and its impact on cancer pathogenesisKarishma Sajnani, Farhadul Islam, Robert Anthony Smith, et al.
Annals of Diagnostic Pathology|December 17, 2013
Expression profile of endothelin 1 and its receptor endothelin receptor A in papillary thyroid carcinoma and their correlations with clinicopathologic characteristicsSoussan Irani, Ali Salajegheh, Vinod Gopalan, et al.
Human Pathology|December 21, 2010
Correlation between BRAF mutation and the clinicopathological parameters in papillary thyroid carcinoma with particular reference to follicular variantRobert Anthony Smith, Ali Salajegheh, Stephen Weinstein, et al.
Biology of the Cell|May 3, 2012
Epithelial-mesenchymal transition and mesenchymal-epithelial transition are essential for the acquisition of stem cell properties in hTERT-immortalised oral epithelial cellsBin Qiao, Vinod Gopalan, Zhifeng Chen, et al.
Pageof 3